Update on diabetic neuropathy

Zachary Simmons, Eva L. Feldman

Research output: Contribution to journalReview article

117 Citations (Scopus)

Abstract

Purpose of review: This review will focus on recent advances in the field of diabetic neuropathy, with an emphasis on distal symmetric sensory and sensorimotor polyneuropathy. Some new information in the areas of diabetic amyotrophy and diabetic autonomic neuropathy will also be reviewed. Recent findings: The pathogenesis of diabetic neuropathy is multifactorial. There is increasing evidence to link abnormalities in the polyol pathway to the pathogenesis of diabetic neuropathy. In addition, there appear to be abnormalities of nerve regeneration and of sodium and calcium channels. Aldose reductase inhibitors have shown promise in animal models for reversing neuropathy if started early and used for a sufficient time, but those used to date in human trials are probably not of sufficient potency. Neurotrophic factors and vascular endothelial growth factor both also show promise. Specific recommendations and pathways for diabetic foot care have been devised. Lamotrigine and bupropion represent new treatments for neuropathic pain. The role of impaired glucose tolerance is being explored as it relates to polyneuropathy. Summary: An increasing understanding of the pathogenetic mechanisms holds out promise for the effective treatment of diabetic neuropathy. The early detection of abnormal glucose metabolism is particularly important, as treatments will probably be most effective if administered early in the course of the neuropathy, when abnormalities of peripheral nerves are more likely to be reversible.

Original languageEnglish (US)
Pages (from-to)595-603
Number of pages9
JournalCurrent Opinion in Neurology
Volume15
Issue number5
DOIs
StatePublished - Oct 1 2002

Fingerprint

Diabetic Neuropathies
Polyneuropathies
Bupropion
Aldehyde Reductase
Nerve Regeneration
Diabetic Foot
Glucose Intolerance
Sodium Channels
Nerve Growth Factors
Neuralgia
Calcium Channels
Peripheral Nerves
Vascular Endothelial Growth Factor A
Therapeutics
Animal Models
Glucose

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Simmons, Zachary ; Feldman, Eva L. / Update on diabetic neuropathy. In: Current Opinion in Neurology. 2002 ; Vol. 15, No. 5. pp. 595-603.
@article{2d2ea5e26df34e5ab76a989e4a97a784,
title = "Update on diabetic neuropathy",
abstract = "Purpose of review: This review will focus on recent advances in the field of diabetic neuropathy, with an emphasis on distal symmetric sensory and sensorimotor polyneuropathy. Some new information in the areas of diabetic amyotrophy and diabetic autonomic neuropathy will also be reviewed. Recent findings: The pathogenesis of diabetic neuropathy is multifactorial. There is increasing evidence to link abnormalities in the polyol pathway to the pathogenesis of diabetic neuropathy. In addition, there appear to be abnormalities of nerve regeneration and of sodium and calcium channels. Aldose reductase inhibitors have shown promise in animal models for reversing neuropathy if started early and used for a sufficient time, but those used to date in human trials are probably not of sufficient potency. Neurotrophic factors and vascular endothelial growth factor both also show promise. Specific recommendations and pathways for diabetic foot care have been devised. Lamotrigine and bupropion represent new treatments for neuropathic pain. The role of impaired glucose tolerance is being explored as it relates to polyneuropathy. Summary: An increasing understanding of the pathogenetic mechanisms holds out promise for the effective treatment of diabetic neuropathy. The early detection of abnormal glucose metabolism is particularly important, as treatments will probably be most effective if administered early in the course of the neuropathy, when abnormalities of peripheral nerves are more likely to be reversible.",
author = "Zachary Simmons and Feldman, {Eva L.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1097/00019052-200210000-00010",
language = "English (US)",
volume = "15",
pages = "595--603",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Update on diabetic neuropathy. / Simmons, Zachary; Feldman, Eva L.

In: Current Opinion in Neurology, Vol. 15, No. 5, 01.10.2002, p. 595-603.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Update on diabetic neuropathy

AU - Simmons, Zachary

AU - Feldman, Eva L.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Purpose of review: This review will focus on recent advances in the field of diabetic neuropathy, with an emphasis on distal symmetric sensory and sensorimotor polyneuropathy. Some new information in the areas of diabetic amyotrophy and diabetic autonomic neuropathy will also be reviewed. Recent findings: The pathogenesis of diabetic neuropathy is multifactorial. There is increasing evidence to link abnormalities in the polyol pathway to the pathogenesis of diabetic neuropathy. In addition, there appear to be abnormalities of nerve regeneration and of sodium and calcium channels. Aldose reductase inhibitors have shown promise in animal models for reversing neuropathy if started early and used for a sufficient time, but those used to date in human trials are probably not of sufficient potency. Neurotrophic factors and vascular endothelial growth factor both also show promise. Specific recommendations and pathways for diabetic foot care have been devised. Lamotrigine and bupropion represent new treatments for neuropathic pain. The role of impaired glucose tolerance is being explored as it relates to polyneuropathy. Summary: An increasing understanding of the pathogenetic mechanisms holds out promise for the effective treatment of diabetic neuropathy. The early detection of abnormal glucose metabolism is particularly important, as treatments will probably be most effective if administered early in the course of the neuropathy, when abnormalities of peripheral nerves are more likely to be reversible.

AB - Purpose of review: This review will focus on recent advances in the field of diabetic neuropathy, with an emphasis on distal symmetric sensory and sensorimotor polyneuropathy. Some new information in the areas of diabetic amyotrophy and diabetic autonomic neuropathy will also be reviewed. Recent findings: The pathogenesis of diabetic neuropathy is multifactorial. There is increasing evidence to link abnormalities in the polyol pathway to the pathogenesis of diabetic neuropathy. In addition, there appear to be abnormalities of nerve regeneration and of sodium and calcium channels. Aldose reductase inhibitors have shown promise in animal models for reversing neuropathy if started early and used for a sufficient time, but those used to date in human trials are probably not of sufficient potency. Neurotrophic factors and vascular endothelial growth factor both also show promise. Specific recommendations and pathways for diabetic foot care have been devised. Lamotrigine and bupropion represent new treatments for neuropathic pain. The role of impaired glucose tolerance is being explored as it relates to polyneuropathy. Summary: An increasing understanding of the pathogenetic mechanisms holds out promise for the effective treatment of diabetic neuropathy. The early detection of abnormal glucose metabolism is particularly important, as treatments will probably be most effective if administered early in the course of the neuropathy, when abnormalities of peripheral nerves are more likely to be reversible.

UR - http://www.scopus.com/inward/record.url?scp=0036797742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036797742&partnerID=8YFLogxK

U2 - 10.1097/00019052-200210000-00010

DO - 10.1097/00019052-200210000-00010

M3 - Review article

C2 - 12352003

AN - SCOPUS:0036797742

VL - 15

SP - 595

EP - 603

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 5

ER -